Justin Kopit

8.6k total citations · 2 hit papers
12 papers, 2.2k citations indexed

About

Justin Kopit is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Justin Kopit has authored 12 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Justin Kopit's work include Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Multiple Myeloma Research and Treatments (3 papers). Justin Kopit is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Multiple Myeloma Research and Treatments (3 papers). Justin Kopit collaborates with scholars based in United States, France and Spain. Justin Kopit's co-authors include Leonard B. Saltz, Neal J. Meropol, Michael N. Needle, Patrick J. Loehrer, Robert J. Mayer, O. Kisker, Alberto Sobrero, Werner Scheithauer, Joan Maurel and Christophe Borg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Hepatology.

In The Last Decade

Justin Kopit

12 papers receiving 2.2k citations

Hit Papers

Phase II Trial of Cetuximab in Patients With Refractory C... 2004 2026 2011 2018 2004 2008 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
    2004 1.4k citations Leonard B. Saltz, Neal J. Meropol et al. Journal of Clinical Oncology profile →
  2. EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
    2008 726 citations Alberto Sobrero, Joan Maurel et al. Journal of Clinical Oncology profile →

Peers

Justin Kopit
David J. Mauro United States
Guy A. Van Hazel Australia
Jean‐Luc Canon Belgium
C.-H. Köhne Germany
Harm Sinnige Netherlands
Marianne Krahn Canada
Vinod Ganju Australia
Martin Šmakal United States
Nobuyuki Mizunuma Japan
David J. Mauro United States
Justin Kopit
Citations per year, relative to Justin Kopit Justin Kopit (= 1×) peers David J. Mauro

Countries citing papers authored by Justin Kopit

Since Specialization
Citations

This map shows the geographic impact of Justin Kopit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justin Kopit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justin Kopit more than expected).

Fields of papers citing papers by Justin Kopit

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justin Kopit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justin Kopit. The network helps show where Justin Kopit may publish in the future.

Co-authorship network of co-authors of Justin Kopit

This figure shows the co-authorship network connecting the top 25 collaborators of Justin Kopit. A scholar is included among the top collaborators of Justin Kopit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justin Kopit. Justin Kopit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Ferris, Robert L., George R. Blumenschein, Jérôme Fayette, et al.. (2016). Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.. Journal of Clinical Oncology. 34(15_suppl). 6009–6009. 41 indexed citations
3.
Kao, Jia‐Horng, Boris Yoffe, William Sievert, et al.. (2014). P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDY. Journal of Hepatology. 60(1). S527–S528. 7 indexed citations
4.
Lonial, Sagar, Paul G. Richardson, Philippe Moreau, et al.. (2012). ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004).. Journal of Clinical Oncology. 30(15_suppl). TPS8112–TPS8112. 4 indexed citations
5.
Jakubowiak, Andrzej, Darrell White, Philippe Moreau, et al.. (2012). A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).. Journal of Clinical Oncology. 30(15_suppl). TPS8114–TPS8114. 1 indexed citations
6.
Dimopoulos, Meletios Α., Thierry Façon, Paul G. Richardson, et al.. (2012). ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006).. Journal of Clinical Oncology. 30(15_suppl). TPS8113–TPS8113. 16 indexed citations
7.
Chow, Laura Q.M., Scott A. Laurie, Chandra P. Belani, et al.. (2010). Phase I trial of BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2547–2547. 6 indexed citations
8.
Richardson, Paul G., Asher Chanan‐Khan, Sagar Lonial, et al.. (2009). Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study.. Blood. 114(22). 2890–2890. 8 indexed citations
9.
Sobrero, Alberto, Joan Maurel, Louis Fehrenbacher, et al.. (2008). EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 26(14). 2311–2319. 726 indexed citations breakdown →
10.
Sobrero, Alberto, Werner Scheithauer, Joan Maurel, et al.. (2005). Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of the first 400 patients in a randomized phase III trial (EPIC). Journal of Clinical Oncology. 23(16_suppl). 3580–3580. 6 indexed citations
11.
Saltz, Leonard B., Neal J. Meropol, Patrick J. Loehrer, et al.. (2004). Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor. Journal of Clinical Oncology. 22(7). 1201–1208. 1383 indexed citations breakdown →
12.
Sun, Weijing, James Stevenson, David J. Vaughn, et al.. (2003). Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.. PubMed. 9(14). 5221–7. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David J. Mauro Breakdown of academic impact, for papers by Guy A. Van Hazel Breakdown of academic impact, for papers by Jean‐Luc Canon Breakdown of academic impact, for papers by C.-H. Köhne Breakdown of academic impact, for papers by Harm Sinnige Breakdown of academic impact, for papers by Marianne Krahn Breakdown of academic impact, for papers by Vinod Ganju Breakdown of academic impact, for papers by Martin Šmakal Breakdown of academic impact, for papers by Nobuyuki Mizunuma
Rankless by CCL
2026